Cargando…

Pretreatment inflammatory indices predict Bevacizumab response in recurrent Glioma

Aim: It remains unclear what the best therapeutic option for recurrent glioma patients after Stupp treatment is. Bevacizumab (BVZ) is commonly administered in progression, but it appears that only some patients benefit. It would be useful to find biomarkers that determine beforehand who these patien...

Descripción completa

Detalles Bibliográficos
Autores principales:	Martínez-González, Alicia, Cabrera, Raquel, Lloret, Marta, Lara, Pedro C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	OAE Publishing Inc. 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8992487/ https://www.ncbi.nlm.nih.gov/pubmed/35582438 http://dx.doi.org/10.20517/cdr.2020.33

Ejemplares similares

Bevacizumab in recurrent WHO grades II–III glioma
por: Annakib, Soufyan, et al.
Publicado: (2023)

Bevacizumab in Recurrent Glioma: Patterns of Treatment Failure and Implications
por: Li, Yi, et al.
Publicado: (2017)

Geometrical Measures Obtained from Pretreatment Postcontrast T1 Weighted MRIs Predict Survival Benefits from Bevacizumab in Glioblastoma Patients
por: Molina, David, et al.
Publicado: (2016)

Post-bevacizumab Clinical Outcomes and the Impact of Early Discontinuation of Bevacizumab in Patients with Recurrent Malignant Glioma
por: Cha, Yongjun, et al.
Publicado: (2017)

Activity and Safety of Bevacizumab Plus Fotemustine for Recurrent Malignant Gliomas
por: Vaccaro, V., et al.
Publicado: (2014)

Disease progression patterns of bevacizumab responders with recurrent malignant gliomas
por: Kim, Ju-Hwi, et al.
Publicado: (2017)

Recurrence pattern analysis after re-irradiation with bevacizumab in recurrent malignant glioma patients
por: Niyazi, Maximilian, et al.
Publicado: (2014)

Bevacizumab and irinotecan in recurrent malignant glioma, a single institution experience
por: Mesti, Tanja, et al.
Publicado: (2015)

Radiographic patterns of recurrence and pathologic correlation in malignant gliomas treated with bevacizumab
por: Thomas, Alissa, et al.
Publicado: (2018)

Bevacizumab in recurrent glioblastoma
por: Martinez, Nina L., et al.
Publicado: (2019)

Bevacizumab toxicity in heavily pretreated recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancers
por: Martin, Jovana Y., et al.
Publicado: (2016)

Pretreatment Neutrophil-to-Lymphocyte Ratio as a Predictive Marker of Response to Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma
por: Eso, Yuji, et al.
Publicado: (2021)

Pulsed Reduced Dose Rate Radiotherapy in Conjunction With Bevacizumab or Bevacizumab Alone in Recurrent High-grade Glioma: Survival Outcomes
por: Bovi, Joseph A., et al.
Publicado: (2020)

Bevacizumab for Patients with Recurrent Gliomas Presenting with a Gliomatosis Cerebri Growth Pattern
por: Burger, Michael C., et al.
Publicado: (2017)

Identification of transcriptome signature for predicting clinical response to bevacizumab in recurrent glioblastoma
por: Choi, Seung Won, et al.
Publicado: (2018)

Eosinophil and lymphocyte counts predict bevacizumab response and survival in recurrent glioblastoma
por: Vaios, Eugene J, et al.
Publicado: (2020)

Phase II Study of Single-agent Bevacizumab in Japanese Patients with Recurrent Malignant Glioma(†)
por: Nagane, Motoo, et al.
Publicado: (2012)

Angiotensinogen promoter methylation predicts bevacizumab treatment response of patients with recurrent glioblastoma
por: Urup, Thomas, et al.
Publicado: (2020)

A systematic review of the utility of amino acid PET in assessing treatment response to bevacizumab in recurrent high-grade glioma
por: Hughes, Kendall L, et al.
Publicado: (2021)

ITGA5 Predicts Dual-Drug Resistance to Temozolomide and Bevacizumab in Glioma
por: Shi, Ying, et al.
Publicado: (2021)

Phase II Study to Evaluate the Efficacy and Safety of Rilotumumab and Bevacizumab in Subjects with Recurrent Malignant Glioma
por: Affronti, Mary Lou, et al.
Publicado: (2018)

Patterns of long-term survivorship following bevacizumab treatment for recurrent glioma: a case series
por: Liu, Liang Yen, et al.
Publicado: (2019)

Circulating PD-L1 levels change during bevacizumab-based treatment in recurrent glioma
por: Mair, Maximilian J., et al.
Publicado: (2021)

Bevacizumab in recurrent high-grade glioma: a single institution retrospective analysis on 92 patients
por: Detti, Beatrice, et al.
Publicado: (2021)

Radiological Recurrence Patterns after Bevacizumab Treatment of Recurrent High-Grade Glioma: A Systematic Review and Meta-Analysis
por: Cho, Se Jin, et al.
Publicado: (2020)

Pretreatment with antibiotics is associated with reduced therapeutic response to atezolizumab plus bevacizumab in patients with hepatocellular carcinoma
por: Maesaka, Kazuki, et al.
Publicado: (2023)

Durable response to bevacizumab in adults with recurrent pilocytic astrocytoma
por: Wasilewski, Andrea, et al.
Publicado: (2018)

Effects of bevacizumab plus irinotecan on response and survival in patients with recurrent malignant glioma: a systematic review and survival-gain analysis
por: Xu, Tao, et al.
Publicado: (2010)

CD44 expression in the tumor periphery predicts the responsiveness to bevacizumab in the treatment of recurrent glioblastoma
por: Nishikawa, Masahiro, et al.
Publicado: (2021)

Radiotherapy versus combination radiotherapy-bevacizumab for the treatment of recurrent high-grade glioma: a systematic review
por: Kulinich, Daniel P., et al.
Publicado: (2021)

Bevacizumab for the Treatment of Recurrent Glioblastoma
por: Chamberlain, Marc C.
Publicado: (2011)

Efficacy and safety of aflibercept in metastatic colorectal cancer pretreated with bevacizumab: A report of five cases
por: Alcaide, Julia, et al.
Publicado: (2016)

Rapid response to systemic bevacizumab therapy in recurrent respiratory papillomatosis
por: MOHR, MICHAEL, et al.
Publicado: (2014)

Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study
por: Reardon, D A, et al.
Publicado: (2009)

Boron neutron capture therapy with bevacizumab may prolong the survival of recurrent malignant glioma patients: four cases
por: Miyatake, Shin-Ichi, et al.
Publicado: (2014)

Phase II Study of Bevacizumab and Vorinostat for Patients with Recurrent World Health Organization Grade 4 Malignant Glioma
por: Ghiaseddin, Ashley, et al.
Publicado: (2017)

RT-05 THE RESULTS OF GAMMA KNIFE RADIOSURGERY WITH BEVACIZUMAB (AVAGAMMA THERAPY) FOR RECURRENT GRADE II/III GLIOMAS
por: Asanome, Taku, et al.
Publicado: (2019)

Integrin Inhibitor Suppresses Bevacizumab-Induced Glioma Invasion()()
por: Ishida, Joji, et al.
Publicado: (2014)

Delivery of bevacizumab by intracranial injection: assessment in glioma model
por: Liu, Yu-Xiao, et al.
Publicado: (2018)

Overexpression of CD99 is associated with tumor adaptiveness and indicates the tumor recurrence and therapeutic responses in gliomas
por: Shang, Erfei, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_fomk3uapfreserie3suqu649og